Adverse drug event burden characterization and serum biomarkers. (A) AEs including hematological toxicity, organ function toxicity, other laboratory test abnormalities, CRS, and neurotoxicity during the 30 days after axi-cel infusion are shown (rows) for 416 individual patients (columns), with bars indicating the number of events and colors representing severity. The median durations of (B) milder (grade <3) and (C) severe (grade ≥3) AEs, with the color shades indicating the rates (%) of RW patients developing such AEs.